The Treatment of Diffuse Large B-Cell Lymphoma (Triple Expression) Involving the Breast, Spleen , and Bone in a Male Patient with Viral Hepatitis B: A Rare Case Report

被引：0

作者：

Zhou, Weiling ^{[1
]}

Gao, Qian ^{[1
]}

Wang, Lianjing ^{[2
]}

Li, Weijing ^{[2
]}

He, Cuiying ^{[2
]}

Li, Yanting ^{[3
]}

Feng, Lei ^{[1
]}

Liu, Wei ^{[2
]}

Liu, Lihong ^{[2
]}

Wang, Yuan ^{[1
]}

机构：

[1] Hebei Med Univ, Hosp 4, Dept Endocrine & Metab Dis, Shijiazhuang 050000, Hebei, Peoples R China

[2] Hebei Med Univ, Hosp 4, Dept Hematol, Shijiazhuang 050000, Hebei, Peoples R China

[3] Hebei Med Univ, Hosp 2, Dept Glandular Surg, Shijiazhuang 050000, Hebei, Peoples R China

来源：

CANCER MANAGEMENT AND RESEARCH | 2023年 / 15卷

关键词：

breast; viral hepatitis B; diffuse large B-cell lymphoma; triple expression; autologous stem cell transplantation;

D O I：

10.2147/CMAR.S427217

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Diffuse large B-cell lymphoma (DLBCL) involving the breast, spleen, and bone in a male patient with hepatitis B virus (HBV) infection is extremely rare in clinical practice.Case Presentation: We report a case of DLBCL involving the breast, spleen, and bone (triple expression of Bcl-2+, Bcl-6+, and 70% positive C-mcy) in a male patient with HBV admitted to our hospital. The patient was treated with EPOCHx4, lenalidomide +EPOCHx2 chemotherapy, intermittent methotrexate intrathecal injections to prevent central invasion, and autologous stem cell transplantation (ASCT). The patient is currently in complete remission, and the follow-up time was 43 months.Conclusion: A patient with DLBCL involving the breast, spleen, and bone can be treated with a combination of multiple regimens. If the patient's economic conditions permit it, ASCT can be considered.

引用

页码：983 / 988

页数：6

共 13 条

[1] Cortez Afonso José Pereira, 2011, Rev. Bras. Hematol. Hemoter., V33, P10, DOI 10.5581/1516-8484.20110007
[2] Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study
Engels, Eric A.
Cho, Eo Rin
Jee, Sun Ha
[J]. LANCET ONCOLOGY, 2010, 11 (09) : 827 - 834
[3] Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities
Marcucci, Fabrizio
Mele, Alfonso
[J]. BLOOD, 2011, 117 (06) : 1792 - 1798
[4] Sabate J M, 2002, Breast J, V8, P294, DOI 10.1046/j.1524-4741.2002.08509.x
[5] seer.cancer, 2020, Cancer stat-facts non-Hodgkin's lymphoma
[6] New Insights into Diffuse Large B-Cell Lymphoma Pathobiology
Solimando, Antonio Giovanni
Annese, Tiziana
Tamma, Roberto
Ingravallo, Giuseppe
Maiorano, Eugenio
Vacca, Angelo
Specchia, Giorgina
Ribatti, Domenico
[J]. CANCERS, 2020, 12 (07) : 1 - 22
[7] Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis
Sun, Lova
Li, Shuli
El-Jawahri, Areej
Armand, Philippe
Dey, Bimalangshu R.
Fisher, David C.
Jacobsen, Eric D.
Jacobson, Caron A.
LaCasce, Ann S.
McAfee, Steven L.
Spitzer, Thomas R.
Chen, Yi-Bin
DeFilipp, Zachariah
[J]. ONCOLOGIST, 2018, 23 (05) : 624 - 630
[8] Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma
Tardy M.P.
Gastaud L.
Ojeda-Uribe M.
Boscagli A.
Caruso S.
Skaf R.
Gutnecht J.
Thyss A.
Peyrade F.
[J]. Experimental Hematology & Oncology, 4 (1)
[9] WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1
[10] WISEMAN C, 1972, CANCER, V29, P1705, DOI 10.1002/1097-0142(197206)29:6<1705::AID-CNCR2820290640>3.0.CO

← 1 2 →